Who are CHOP combined with CMAB304's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chop-combined-with-cmab304.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

CHOP combined with CMAB304 — Competitive Intelligence Brief

CHOP combined with CMAB304 (CHOP combined with CMAB304) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: chemotherapy + monoclonal antibody. Area: Oncology.

phase 3 Combination therapy: chemotherapy + monoclonal antibody Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CHOP combined with CMAB304 (CHOP combined with CMAB304) — Shanghai CP Guojian Pharmaceutical Co., Ltd.. CHOP chemotherapy combined with CMAB304 (a monoclonal antibody) targets cancer cells through cytotoxic chemotherapy while enhancing immune response through antibody-mediated mechanisms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CHOP combined with CMAB304 TARGET	CHOP combined with CMAB304	Shanghai CP Guojian Pharmaceutical Co., Ltd.	phase 3	Combination therapy: chemotherapy + monoclonal antibody

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: chemotherapy + monoclonal antibody class)

Shanghai CP Guojian Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CHOP combined with CMAB304 — Competitive Intelligence Brief. https://druglandscape.com/ci/chop-combined-with-cmab304. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab